An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy
Phase: PHASE2
Conditions: Female Breast Carcinoma, Female Ductal Carcinoma In Situ
Sponsor: Atossa Therapeutics, Inc.

 
 
 
 
Clinical Protocol Version K 
 
Dated Jan 6, 2020 
 
Protocol Title: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical 
Intramuscular and Intraductal Fulvestrant in Women with Invasive Breast Cancer 
or DCIS Undergoing Mastectomy or Lumpectomy 
 
NCT: 02540330

 
 
 
1 
 
An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular 
and Intraductal Fulvestrant in Women with Invasive Breast Cancer or DCIS 
Undergoing Mastectomy or Lumpectomy 
 
Protocol Number: 
ATOS-2015-007 
Protocol Date: 
Jan 06, 2020  
Protocol Version 
K 
Sponsor: 
Atossa Genetics, Inc. 
107 Spring Street, 
Seattle, WA 98104 
 
Responsible Personnel (Sponsor):       
Steven C Quay, MD, PhD, FCAP 
CEO & President Atossa Genetics 
+1.206.419.4873 
E-mail:steven.quay@atossagenetics.com 
Sponsor Representative: 
Janet R Rea, MSPH, RAC 
SVP, Regulatory, Quality & Clinical Affairs 
1-206.799.7186 
janet.rea@atossagenetics.com 
 
Protocol Revision Record 
Original Protocol: Rev. A; August 12, 2015 
Protocol Revision Record: 
Date: 
Revision Letter: 
September 11, 2015 
B 
September 11, 2015 
C 
October 23, 2015 
D 
March 11, 2016 
E 
April 26, 2016 
F 
August 29, 2016 
G 
June 21, 2017 
H 
June 20 2018 
I 
April 23, 2019 
J 
Jan 06, 2020 
K 
 
The following signatures verify that the Clinical Research Study presented in this protocol is clearly 
understood and agreed upon. The requirements of the protocol including study design, subject selection, 
and expected outcomes are consistent with the technology being studied. The effort is feasible in terms 
of resources and testing requirements. Upon approval, this protocol may be implemented provided the 
appropriate institutional review board or ethics committee approval has been obtained and the Investigator’s 
Agreement associated with the implementation of this study has been completed. 
 
Signature of Sponsor Representative:  
Name of Sponsor Representative:  Janet R Rea, MSPH, RAC 
Date: 
 
 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
2 
 
1.0 
INVESTIGATOR’S AGREEMENT 
I have received a copy of the protocol number ATOS-2015-007, entitled “An Open Label, 
Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in 
Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy”, 
Version K” dated January 06, 2020, from Atossa Genetics, Inc.  I agree to the conditions as 
set out in this protocol and fully accept that any change requires prior written approval from 
Atossa. Additionally, I agree to carry out this protocol in accordance with ICH Guidelines; all 
applicable US Regulations (21 CFR parts 50, 54, 56 and 312) and Good Clinical Practice 
Guidelines, as applicable. Finally, I will ensure that the investigational agent and/or device 
will be used only as described in this protocol. 
The information contained in this protocol is provided to me in confidence, for review only 
by myself, the Independent Ethics Committee/Investigational Review Board authorized to 
review and approve the study at this study site, the designated research staff participating in 
this clinical study, and applicable regulatory agencies. 
I understand that the information/technology contained in this protocol is proprietary and may 
not be disclosed to any other party, in any form, without prior authorization from Atossa, 
except to the extent necessary to obtain informed consent from potential study participants. 
 
 
 
Signature of Investigator; Date Signed  
 
 
Lisa Jacobs, MD  
 
 
 
 
 
 
 
 
 
Date 
 
 
 
 
 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
3 
 
TABLE OF CONTENTS 
1.0 
INVESTIGATOR’S AGREEMENT ..................................................................................... 2 
Table of Contents ................................................................................................................................ 3 
2.0 
Clinical Trial Synopsis ........................................................................................................... 6 
3.0 
List of Abbreviations & Definition of Terms ......................................................................... 8 
4.0 
Background Information ....................................................................................................... 9 
5.0 
Clinical Use of the Anti-Estrogen Fulvestrant (Faslodex®) ............................................. 11 
 
Intraductal Doses of Cytotoxic versus Endocrine Agents ......................................................... 12 
 
Intraductal Effects of Endocrine Agents .................................................................................... 13 
 
Drug Plasma Concentration Levels ............................................................................................ 13 
6.0 
Trial Objectives and Purposes ............................................................................................. 13 
 ................................................................................................................ 13 
7.0 
Trial Design ........................................................................................................................... 13 
8.0 
Selection and Withdrawal of Subjects ................................................................................ 14 
 ....................................................................................................................... 14 
8.1.1 
Inclusion Criteria: ......................................................................................................... 14 
8.1.2 
Exclusion Criteria: ........................................................................................................ 15 
9.0 
Treatment of Subjects ........................................................................................................... 16 
9.3.1 
Intramuscular Administration of Fulvestrant .............................................................................. 17 
9.3.2 
Intraductal Administration of Fulvestrant ................................................................................... 17 
9.3.3 
Plasma Drug Concentration Levels ............................................................................................ 18 
9.3.4 
Post Fulvestrant Administration and Pre-Surgery Assessment ................................................... 18 
9.12.1 Name of Medical Devices ............................................................................................ 22 
9.12.2 Indications for Use of the Medical Devices.................................................................. 22 
9.12.3 Description of the Investigational Medical Device ...................................................... 23 
9.13.1 Storage and Handling and Stability .............................................................................. 25 
9.13.2 Device Dispensing ........................................................................................................ 25 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
4 
 
10.0 
Assessment of Efficacy ......................................................................................................... 25 
10.2.1 Fulvestrant PK Analysis ............................................................................................... 25 
11.0 
Assessment of Safety ............................................................................................................ 26 
11.2.1 Adverse Events ............................................................................................................. 26 
11.2.2 Adverse Event (AE) Definition .................................................................................... 27 
11.2.3 AE Intensity Classification ........................................................................................... 28 
11.2.4 AE Relationship Classification ..................................................................................... 28 
11.2.5 SAE Definition ............................................................................................................. 28 
11.2.6 Procedures for Adverse Event Reporting ..................................................................... 29 
12.0 
Accountability, Risks and Benefits ..................................................................................... 30 
13.0 
Statistics ................................................................................................................................. 30 
14.0 
Direct Access to Source Data/Documents ........................................................................... 32 
15.0 
Quality Control and Quality Assurance ............................................................................. 33 
16.0 
Ethics ..................................................................................................................................... 35 
17.0 
Data Handling and Record Keeping ................................................................................... 36 
18.0 
Publication Policy ................................................................................................................. 38 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
5 
 
19.0 
References ............................................................................................................................. 40 
20.0 
Appendices ............................................................................................................................ 42 
 
 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
6 
 
2.0 
CLINICAL TRIAL SYNOPSIS 
Study Title 
An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and 
Intraductal Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing 
Mastectomy or Lumpectomy 
Study Number 
ATOS-2015-007 
Objectives 
To study the safety and tolerability of intraductal administration of fulvestrant (Faslodex®, 
ICI 182,780) in women with Stage 1 or 2 invasive ductal carcinoma (or mixed ductal and 
lobular) or DCIS, prior to mastectomy or lumpectomy. 
To determine the pathological effects, specifically changes in Ki67, ER/PgR expression 
between the pre-fulvestrant biopsy and the post-fulvestrant surgical specimen. 
To compare an abbreviated (Pharmacokinetic-PK) profile of standard intramuscularly 
administered (500 mg) with the intraductal instillation of single-dose (500 mg maximum) 
fulvestrant. To determine and compare breast tissue fulvestrant distribution. 
Study Drug 
Fulvestrant (Faslodex®) 
Study Design 
This is a single-dose observational and comparative study 
No. of Subjects 
30 evaluable subjects with breast cancer and scheduled for mastectomy or lumpectomy. 
Routes of 
Administration 
Intramuscularly (n = 6) and intraductally (n = 24) 
Dosage  
(Single dose) 
Intramuscularly: 500 mg – to establish reference proliferation markers (Ki67) responses and 
PK-values. 
Intraductally: up to 500 mg 
Delivery Device 
Intramuscularly: Fulvestrant is supplied, from the manufacturer, as two, 5-mL prefilled 
syringes, containing 50 mg/mL (250 mg/syringe) 
Intraductally: Jabczenski Ductogram Cannula® Microcatheter or IntrocanSafety® IV 
Catheter and the FullCYTE® Breast Aspirator. Detailed instructions for intraductal 
fulvestrant administration are located in the administration manual provided 
Inclusion Criteria 
1. 
Female 
2. 
18 years of age or older 
3. 
Scheduled to undergo mastectomy or lumpectomy for Invasive Breast Cancer 
(clinical stage 1 or 2, ER+ low- to medium grade) or DCIS 
4. 
Pathological diagnosis of Invasive Ductal Carcinoma or Ductal Carcinoma in Situ 
(DCIS) requiring mastectomy or lumpectomy. Mixed ductal and lobular tumors are 
permitted). 
5. 
Estrogen Receptor positive biopsy, as determined from a biopsy specimen obtained 
no more than 3 months prior to entry 
6. 
ECOG performance scale of 0-1 (Appendix A) 
7. 
Adequate organ function as defined by the following criteria: 
a. 
Absolute neutrophil count (ANC) ≥ 1500/μL 
b. 
Platelets ≥ 100,000/μL 
c. 
Hemoglobin ≥ 9.0 g/dL 
d. 
Creatinine ≤ 2 times upper limit of normal 
e. 
Bilirubin ≤ 2 times upper limit of normal 
f. 
Transaminases (AST/SGOT and ALT/SGPT) ≤ 2.5 times upper limit of 
normal 
8. 
Able to sign informed consent 
9. 
Willing to use effective contraception for at least 100-days post study drug 
administration if subject is pre-menopausal. 
 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
7 
 
Exclusion Criteria 
1. 
Concurrent treatment with another anti-estrogen 
2. 
Presence of an active infection requiring systemic therapy. 
3. 
The following conditions contra-indicating fulvestrant administration: 
a. 
Subjects with bleeding diatheses, thrombocytopenia or current anticoagulant 
use (excludes aspirin or anti-inflammatory agents) 
b. 
Subjects with a known hypersensitivity to fulvestrant or any of its formulation 
components including castor oil, alcohol, benzyl alcohol, and benzyl benzoate. 
c. 
Severe hepatic impairment.  
4. 
Prior surgery on the ipsilateral breast which interrupts communication of the ductal 
systems with the nipple 
5. 
Prior radiation to the breast 
6. 
Pregnant or lactating 
7. 
Impaired cardiac function or history of cardiac problems of NYHA Class 111 and IV 
8. 
Poor nutritional state as indicated by a BMI of below 20  
9. 
Presence of serious infection not controlled with systemic therapy 
10. 
History of allergies to Lidocaine or Novocain 
11. 
Concurrent participation in an experimental drug study  
Study Duration 
Total 12 – 36 months, active phase 6 weeks followed by inactive phase (enrollment 
dependent) 
No. of Trial Sites 
One.  
Study Rationale 
This study is being conducted to develop the preliminary safety and feasibility of this route 
of administration to provide information necessary to develop future clinical studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
8 
 
3.0 
LIST OF ABBREVIATIONS & DEFINITION OF TERMS 
ADH 
Atypical ductal hyperplasia 
AE 
Adverse Event 
AI 
Aromatase inhibitor 
AIC 
Akaike Information Criterion 
Alb 
Albumin 
ALT 
Alanine aminotransferase 
ANC 
Absolute neutrophil count 
AST 
Aspartate aminotransferase 
ATOS 
Atossa Genetics, Inc. 
AUC 
Area under curve 
BSA 
Body Surface Area 
BUN 
Blood urea nitrogen 
CFR 
The United States Code of Federal Regulations 
Cr 
Creatinine 
CRA 
Clinical research associate 
CRF 
Case report form 
CTCAE 
Common Terminology Criteria for Adverse Events 
CTMF 
Clinical Trial Master File 
DMP 
Data Management Plan 
DCIS 
Ductal Carcinoma In Situ 
DLT 
Dose limiting toxicities 
ER 
Estrogen receptor 
FDA 
United States Food and Drug Administration 
GCP 
Good Clinical Practice 
Glu 
Glucose 
HE 
Hematoxylin and eosin 
HPLC 
high performance liquid chromatography 
H & P 
History & Physical 
ICH 
International Conference on Harmonization 
ID 
identification 
IM 
Intramuscular 
IRB/IEC 
Institutional Review Board/Institutional Ethics Committee 
K 
potassium 
mg 
milligrams 
mL 
milliliter 
MRI 
Magnetic resonance imaging 
Na 
Sodium 
NAF 
Nipple aspirate fluid 
NCI 
National Cancer Institute (United States) 
NYHA           New York Heart Association 
PgR 
Progesterone Receptor 
PK 
Pharmacokinetics 
PLD 
Pegylated liposomal doxorubicin, trade name Doxil® 
SGOT 
Serum glutamic oxaloacetic transaminase  
SGPT 
Serum glutamic pyruvic transaminase  
SAE 
Serious adverse event 
SERM 
Selective estrogen receptor modulator 
Tbili 
Total bilirubin 
 
 
 
 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
9 
 
4.0 
BACKGROUND INFORMATION 
Breast cancer is the leading cause of cancer in women in the United States and the 
second leading cause of cancer related death. An estimated 215,000 American women will 
be diagnosed with breast cancer in 2015 and over 39,000 women will die due to their disease. 
Approximately 1 in 8 women in the United States will be diagnosed with breast cancer 
in their lifetime.1  Because of the increased incidence in breast cancer, both in situ and 
invasive, much research has been done to identify those women at risk for the disease and 
ways to prevent it from occurring. Only two Selective Estrogen Receptor Modulators 
(SERMs), tamoxifen and raloxifene, are currently approved in the USA for the prevention of 
breast cancer in high-risk women. The aromatase inhibitors examestane and anastrozole have 
been evaluated successfully in randomized trials, but have not been approved in the US 
specifically for a prevention indication. 
Based upon demographics and registries, data reflect that women whose first-degree 
relatives (e.g., mother, sister or daughter) have had breast cancer are 3 to 4 times more likely 
to develop breast cancer than those without family history. A woman’s reproductive history, 
menopausal status, prior breast surgeries or breast abnormalities also increases her risk of 
developing breast cancer. Currently, several different statistical models, such as the Gail, 
IBIS and Claus models, exist which attempt to predict the 5-year, 10-year and lifetime risk 
of women to develop breast cancer.  The models are based upon the subject’s reproductive 
history as well as family history related to cancer, specifically breast cancer.2 , 3 , 4 These 
models have been useful in identifying subjects at increased risk for developing breast 
cancer, and selection for genetic counseling or more intensive diagnostic surveillance, but do 
not appear to have spurred the development of new chemo-preventive strategies.  The 
mission of this study’s Sponsor, Atossa Genetics Inc. (ATOS), is to reduce the risk for 
breast cancer and reduce the morbidity associated with breast cancer by developing a local, 
minimally invasive therapy with fewer side effects than typically seen with systemic therapy. 
The currently available options for prevention are oophorectomy (surgical removal of the 
ovaries), bilateral mastectomy, or pharmaceutical therapy, such as tamoxifen or anastrozole.5, 
6, 7 None of these options for prevention are without side effects or consequences. 
Oophorectomy is associated with the side effects associated with early menopause. Surgical 
removal of the breast tissue, although successful in reducing the likelihood of developing 
breast cancer by 97% is a lengthy and morbid surgery, not without complications. With long-
term systemic use, tamoxifen puts women at risk for thromboembolism, cataracts, uterine 
cancer, and vasomotor events.7  Much research is being conducted looking at aromatase 
inhibitors (AI) for prevention; however, the risk of osteoporotic fractures and complications, 
such as osteonecrosis of the jaw are substantial with these drugs and may preclude AIs as a 
viable prevention option in a majority of women.8 
Although breast cancers are being detected at a much earlier stage and there is considerable 
work being done with systemically administered agents such as SERMs and AIs to 
prevent breast cancer, little work with regards to prevention has been done with agents 
administered locally, either topically on the skin, or instilled directly into the milk ducts via 
intraductal therapy, as proposed in this study.  It is recognized that the majority of breast 
cancer begins in the lining of the duct.9 Atypical lesions, such as atypical ductal 
hyperplasia (ADH) are thought to progress to ductal carcinoma in situ (DCIS) and to invasive 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
10 
 
cancer, with a diagnosis of ADH conferring a 30-35% lifetime risk of developing invasive 
breast cancer10.  For purposes of preventing breast cancer there is strong rationale to identify 
these epithelial changes and stop them from ever developing in to carcinoma. 
Providing a local therapy into the ducts could reduce the morbidity associated with 
prevention while targeting the potential carcinoma cell. 
This approach is possible because of the anatomy of the breast ductal systems. Cooper did 
extensive studies in 1845, and noted that there were commonly 7-10 ducts.11 
Subsequently, Sartorius performed mammographic studies, and determined there are 5-9 
breast ducts, which coincides with Dietz’s findings.12, 13 A study by Love examined the 
anatomy of the breast using six complementary in vivo and in vitro approaches to determine 
the number, distribution and anatomical properties of the ductal systems of the breast which 
extend from the nipple orifices to the terminal duct lobular units. 14 Over 90% of the nipples 
studied contain 5-9 ductal orifices, generally arranged as a central group and a peripheral 
group. Each nipple orifice communicates with separate non-anastomosing ductal systems 
which extend to the terminal duct lobular units. 
The idea of examining the breast ducts and ductal fluid to understand breast carcinogenesis 
is not a new concept. The first description by LeBourgne in 1946 was termed “ductal 
rinse.”15 He inserted a small catheter into the breast duct and instilled saline, removed 
the catheter and collected the saline as it dripped out of the ductal opening. Subsequently, in 
1958, Papanicolaou, also examined breast duct fluid by placing a suction cup on the nipple 
to elicit small drops of fluid from the breast.16 He studied the cells that were in the fluid in 
an attempt to identify abnormalities or cancer, similar to what had been accomplished by the 
Pap Smear and cervical cytology. Although Papanicolaou was able to identify DCIS in a 
cellular smear of the nipple aspirate fluid (NAF), there was little to be done with the 
procedure as there was no therapy available to women other than a mastectomy, which was 
problematic for those with atypical cells as their significance was still unknown. Because of 
a lack of appropriate therapy and the advent of mammography, the examination of ductal 
fluid and nipple ducts fell to the wayside and was not revisited again until the 1970s. 
Several researchers in the 1970s began examining ductal fluid by utilizing the suction cup 
method and analyzing the NAF.  Their research revealed that the presence of NAF alone 
increased the risk of developing breast cancer. Furthermore, that risk became more 
significant if cellular atypia was identified in the NAF. The risk further increased if the 
woman had a family history of breast cancer.17, 18, 19 Additionally, Sartorius, further 
examined the breast ducts in a similar fashion as LaBourgne, by cannulating the nipple 
ducts whose NAF contained atypical cells under microscopic examination.20 After 
cannulating the ducts, he instilled contrast material, performed a mammogram, then 
collected the contrast material out of the duct and analyzed it under the microscope. His 
research demonstrated that the presence of atypical cells in ductal fluid had a significant 
impact on the risk of developing breast cancer, similar to what had been demonstrated in 
NAF. 
Based upon these compelling results, clinicians began exploring the collection of NAF as 
well as instilling fluid into the ducts and collecting it, “ductal lavage.” One such 
researcher, Love, developed a small catheter to be used to instill fluid as well as collect fluid 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
11 
 
from the breast nipple ducts. The catheter was commercialized through a medical device 
company, ProDuct Health, Inc. (Menlo Park, CA), which was later acquired by Cytyc, Inc. 
(Marlborough, MA, USA) in 2001, which in turn was acquired by Hologic (Waltham, MA, 
USA). Hologic sold the license to the catheters to Atossa Genetics, but unfortunately, it is no 
longer available. 
Initial research shows much promise with regard to intraductal infusion in order to reduce 
the risk of breast cancer. Researchers have recently demonstrated the feasibility of 
intraductal delivery of epirubicin. Goulet and colleagues encapsulated epirubicin, a naturally 
fluorescent anthracycline, into biodegradable nanoparticles. The nanoparticles were then 
administered into mastectomy specimens in the operating room immediately after a 
mastectomy was performed, and the tumor specimen was removed for pathologic 
assessment. They reported that intact epirubicin was seen in the terminal lobules in 8 of 13 
specimens.21 This pilot study demonstrated that it is feasible to use the microcatheter to 
cannulate the breast ducts and infuse a substance throughout a specific duct, all the way to 
the terminal lobules. 
Based upon numerous preclinical studies in rats and mice, Love reported the feasibility of 
administering intraductal pegylated liposomal doxorubicin (PLD) or Doxil® into one duct of 
a woman with a history of breast cancer scheduled for a prophylactic contralateral 
mastectomy in the unaffected side. The subject reported no discomfort during the procedure 
and no problems after the procedure. Six weeks subsequent to the procedure, the subject 
underwent mastectomy histological changes were noted in the lining of the ducts. There was 
not an opportunity to study the effect of the drug on cancer, as the subject was cancer free.22 
More recently, researchers at Johns Hopkins University determined the intraductal approach 
to breast cancer and prevention to be of great importance. Dr. Vered Stearns and her 
colleagues at Johns Hopkins University reported a clinical study administering Doxil into 
the breast ducts containing cancer of women prior to mastectomy. 23 
In collaboration with Dr. Susan Love, Dr. Wei Zhang and the Cancer Institute & Hospital at 
the Chinese Academy of Medical Science conducted a study in 2007 comparing intraductal 
pegylated doxorubicin, methotrexate and carboplatin in 31 women scheduled to undergo 
mastectomy. Published results of this study showed that intraductal administration was 
feasible, but it was suggested that duct perforation led to erratic pharmacokinetics. Study 
results and conclusion warrant the exploration of additional – possibly less toxic, agents for 
intraductal therapy. 24 
Building on to these prior studies with cytotoxic agents, this study utilizes the pure anti- 
estrogen fulvestrant to be injected in up to 5 ducts to determine its effect on the cancer or 
DCIS as well as the safety of this administration method. 
5.0 
CLINICAL USE OF THE ANTI-ESTROGEN FULVESTRANT (FASLODEX®) 
Fulvestrant is the only endocrine therapy targeting the ER receptor that has been shown to 
have efficacy in tamoxifen resistant cancers in Phase 3 clinical trials. Two randomized trials 
have compared the efficacy of fulvestrant 250 mg IM with 1 mg oral anastrozole in 
postmenopausal women with advanced breast cancer whose disease had progressed after 
prior endocrine therapy.31 A combined analysis of these trials showed that fulvestrant was as 
least as effective as anastrozole (5.5 versus 4.1 months, respectively). Based on these trial 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
12 
 
results, fulvestrant gained approval as an intramuscular injection of 250 mg once monthly 
dose level as a second-line treatment for postmenopausal women with hormone- sensitive 
breast cancer.31 
A subsequent randomized trial, CONFIRM, compared 250 mg with 500 mg monthly 
fulvestrant in 736 women and established a 500 mg dose to be superior in terms of 
Progression-free survival. At 18 months median follow-up PFS was 6.5 months in the 500 
mg arm and 5.4 months in the 250 mg arm (p=0.006). This study established 500 mg as the 
standard dose as described in the product labeling in the US and Europe, with a dose of 250 
mg recommended for subjects with moderate hepatic impairment. 31 
Neo-adjuvant use of fulvestrant in postmenopausal women with newly diagnosed invasive 
breast cancer was evaluated in the randomized “NEWEST” Phase 2 study, which 
randomized 211 subjects between 500 mg and 250 mg monthly intramuscular fulvestrant 
(with an extra dose on Day 14 of Month 1) for 16 weeks until surgery. Similar as in the study 
described in this protocol, change in Ki67 proliferation index 4 weeks after fulvestrant was 
the primary endpoint. By 4 weeks, the change from baseline in Ki67 labeling index was 
significantly different between the groups (-78.8 vs. -47.4%, p<0.0001). Changes from 
baseline in ER expression were also significantly different between the groups (p< 0.0002), 
but changes in PgR expression were not. No safety concerns were identified. 25 
 
Intraductal Doses of Cytotoxic versus Endocrine Agents 
Most cytotoxic agents are given based upon BSA, whereas endocrine agents such as 
fulvestrant or tamoxifen are not. 
Consequently, the dose used in this study will not be tailored to BSA or body weight. The 
maximum dose of 500 mg selected for the study is based on US labeled Intra-Muscular (IM) 
dose. Since milk ducts differ in size and volume, it may not be possible to administer 500 mg 
(10 mL) in all subjects. 
It is possible, but unlikely, that peak plasma concentrations of a dose given intraductally will 
reach the same level as the same dose given intramuscularly (IM). This is because the agent 
must diffuse out of the ducts to reach the bloodstream. Eventually the entire dose will be 
taken up systemically but it will happen over a longer period of time (the peak plasma 
concentration will be lower but the area under curve [AUC] should be the same). Hence it 
was decided that the total amount of drug given in a single intraductal installation would not 
be higher than the typical IM dose of fulvestrant.  There will be 5 groups, each consisting of 
6 subjects.  The first subject of each group will receive fulvestrant administered 
intramuscularly and the next 5 subjects will receive fulvestrant intraductally. 
A maximum of two 5 mL vials, each containing 250 mg fulvestrant may be delivered into 
one duct or distributed among up to five ducts targeted for intraductal instillation. Ductal 
systems range in shape, size and volume just as breasts range in shape and size.26 As noted 
before, there are a range of ducts (from 5-9) and each duct within a breast is a different size. 
11, 12, 13 The ductal systems have the capacity to accommodate a significant amount of fluid. In 
a breast feeding woman, a single breast can accommodate anywhere from 47.2 mL to 62.8 
mL .27, 28 In a non-lactating woman, it is estimated that each breast duct can be distended 
with as little as 1 mL and may accommodate up to 20 mL without perforation and only mild 
discomfort.29  Based on prior experience with intraductal therapy it was determined that no 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
13 
 
single breast would be administered > 10 mL of fulvestrant, to be divided among up to 5 
ducts targeted for instillation. This amount, in a non-lactating subject, would limit the risk of 
perforation and discomfort associated with intraductal instillation. 
 
Intraductal Effects of Endocrine Agents 
An important strategy in achieving Atossa’s goal of developing treatments for the prevention 
of breast cancer and tissue-sparing alternatives to radical surgery for those with diagnosed 
breast cancer/DCIS, is to repurpose endocrine agents which are currently available and 
proven to be effective in treating cancer as a method of prevention. In order to study this, 
initially, subjects with invasive breast cancer or DCIS will be evaluated. 
Atossa plans to evaluate the effect of fulvestrant on the ducts with breast cancer/DCIS as 
well as ducts without breast cancer in each subject treated in this trial. 
 
Drug Plasma Concentration Levels 
It is estimated that fulvestrant plasma levels at any given time point will be at most the same 
but more likely less than the levels experienced with IM delivery. It is possible but unlikely 
that fulvestrant will be concentrated in the plasma at the same level as when given IM but 
this will be further assessed in this clinical trial. 
This clinical trial represents a first step to assess the feasibility and safety of intraductal 
endocrine therapy with fulvestrant. Hence an understanding of the pharmacokinetic effects of 
this route of administration is imperative. 
6.0 
TRIAL OBJECTIVES AND PURPOSES 
 
Primary Objective 
To study the safety and tolerability of intraductal administration of fulvestrant (Faslodex, ICI 
182,780) in women with Stage 1 or 2 invasive ductal carcinoma (or mixed ductal and 
lobular) or DCIS, prior to mastectomy or lumpectomy. 
 
Secondary Objectives 
a. To determine the pathological effects, specifically changes in Ki67, ER/PgR 
expression between the pre-fulvestrant biopsy and the post-fulvestrant surgical 
specimen.  
b. To compare an abbreviated (PK) profile of standard intramuscularly administered 
(500 mg) with the intraductal instillation of single-dose (500 mg maximum) 
fulvestrant.  
c. To determine and compare breast tissue fulvestrant distribution. 
 
7.0 
TRIAL DESIGN 
This is an open-label, non-randomized pharmacokinetic study of pre-surgical fulvestrant in 
women scheduled for mastectomy or lumpectomy. Eligible subjects will be identified upon 
admission to the institution for surgical management of breast cancer or DCIS, specifically 
mastectomy or lumpectomy. There will be 5 groups, each consisting of 6 subjects.  The first 
subject of each group will receive fulvestrant administered intramuscularly and the next 5 
subjects will receive fulvestrant intraductally. Subjects where at least 1 suitable duct is 
identified may undergo nipple aspiration in order  to facilitate duct identification and 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
14 
 
intraductal infusion of a fulvestrant accompanied by imaging (saline+ ultrasound). A 
maximum of 5 ducts will receive intraductal infusion of fulvestrant. Across all ducts, the 
total dose will not exceed 500 mg (10 mL). All subjects will be monitored for systemic and 
local adverse events during the procedure, immediately following the procedure, within 30 
minutes, 1 hour, 4 hours and by phone following discharge on Days +1 and +2, +7, and pre-
operative. Subsequent to mastectomy or lumpectomy, subjects will be assessed for systemic 
adverse events until discharge. Per schedule specified in Table 1, subjects will undergo 
serial blood draws to determine fulvestrant blood concentration levels. 
When fulvestrant is administered at or below the dose level of 500 mg currently in routine 
clinical use, emergence of Dose Limiting Toxicities (DLT) is unlikely, but not impossible. 
Since only a single instillation of fulvestrant is given in this protocol, dose reduction in 
individual subjects is not possible. However, if any of the DLT parameters reaches any of 
the thresholds values set in Section 10.3 the dose in subsequent subjects will be reduced to 
250 mg (one 5 mL vial). 
The purpose of this observational study is to understand the safety and tolerability of giving 
the anti-estrogen drug fulvestrant directly into the milk ducts of the breast, and collect any 
evidence of pathologic response. This study will be conducted under good clinical practice 
(GCP) guidelines as outlined in Section 15.5 Good Clinical Practice. This will be a 
single-dose study with two treatment groups: 500 mg administered intramuscularly (n=6) 
and up to 500 mg administered intraductally (n=24). 
 
8.0 
SELECTION AND WITHDRAWAL OF SUBJECTS 
This trial will enroll at least 30 eligible subjects for participation to result in 30 evaluable 
subjects. 
 
Selection Criteria 
8.1.1 Inclusion Criteria: 
1. Female 
2. 18 years of age or older 
3. Scheduled to undergo mastectomy or lumpectomy for Invasive Breast Cancer 
(clinical stage 1 or 2, ER+ low-to intermediate-grade) or DCIS 
4. Pathological diagnosis of Invasive Ductal Carcinoma or Ductal Carcinoma in 
Situ (DCIS) requiring mastectomy or lumpectomy (Mixed ductal and lobular 
carcinoma acceptable) 
5. Estrogen Receptor positive biopsy, as determined from a biopsy specimen 
obtained no more than 3 months prior to entry 
6. ECOG performance scale of 0-1 (Appendix A) 
7. Adequate organ function as defined by the following criteria: 
a. Absolute neutrophil count (ANC) ≥ 1500/μL 
b. Platelets ≥ 100,000/μL 
c. Hemoglobin ≥ 9.0 g/dL 
d. Creatinine ≤ 2 times upper limit of normal 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
15 
 
e. Bilirubin ≤ 2 times upper limit of normal 
f. Transaminases (AST/SGOT and ALT/SGPT) ≤ 2.5 times upper limit of 
normal 
8. Able to sign informed consent 
9. Willing to use effective contraception for at least 100 days post study drug 
administration if subject is pre-menopausal.  
8.1.2 Exclusion Criteria: 
1. Concurrent treatment with another anti-estrogen 
2. Presence of an active infection requiring systemic therapy.  
3. The following conditions contra-indicating fulvestrant administration: 
a. Subjects with bleeding diatheses, thrombocytopenia or current anticoagulant 
use (excluding aspirin and anti-inflammatories) 
b. Subjects with a known hypersensitivity to fulvestrant or any of its formulation 
components including castor oil, alcohol, benzyl alcohol, and benzyl benzoate. 
c. Severe hepatic impairment.  
4. Prior surgery on the ipsilateral breast which interrupts communication of the 
ductal systems with the nipple 
5. Prior radiation to the breast  
6. Pregnant or lactating 
7. Impaired cardiac function or history of cardiac problems of NYHA Class 111 and 
IV (Appendix C 20.4) 
8. Poor nutritional state as indicated by a BMI below 20.   
9. Presence of serious infection not controlled with systemic therapy 
10. History of allergies to Lidocaine or Novocain 
11. Concurrent participation in an experimental drug study. 
 
Inclusion of Special Populations 
Only women will be enrolled in this trial; men lack an anatomically accessible duct system. 
There will not be anyone included under the age of 18 nor will pregnant women participate 
in this trial. All race and ethnic groups are eligible to participate. 
 
Determination of Eligibility 
Once the clinician has obtained a signed informed consent, subjects will be registered with 
the study coordinator and investigator. Additional testing, beyond routine pre-operative 
testing which may be required to determine eligibility, will be performed. This is outlined 
below under Section 9.2 Baseline Assessment After eligibility is established, each subject 
will be assigned a study number to identify them individually. Subjects will not undergo any 
study related drug administration until eligibility is confirmed with additional testing if 
necessary and the subject receives a study number. 
 
Subject Discontinuation 
All subjects have the right to terminate participation in the study at any time. The 
Investigator also has the right to discontinue the subject’s participation at any time 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
16 
 
regardless of whether the subject wishes to continue in the study. The Sponsor may 
discontinue the study at any time. 
In addition, subjects may be withdrawn from the study for the following reasons: 
• Occurrence of a clinically unacceptable AE 
• Violation of the study protocol or lack of compliance with protocol regimens 
• Subject declines further study participation 
• Subject withdraws informed consent 
• Investigator judges it is in the best interest of the subject 
If a subject is withdrawn or discontinues study participation, reasonable efforts will be made 
to bring the subject in to complete the final study procedures. The subject will continue 
to be followed and medically managed in accordance with the arrangement that was in place 
prior to study enrollment. The reason(s) for a subject’s discontinuation from the study are to 
be recorded in the source documentation and on the CRFs.  
Any subject, who voluntarily or involuntarily withdraws from the study prior to mastectomy 
or lumpectomy, will be replaced. 
 
9.0 
TREATMENT OF SUBJECTS 
 
Study Related Procedures 
After each subject has reviewed and signed the informed consent, she will be enrolled in 
the study and assigned a study number as outlined below in Section 17.3 Data Collection 
Requirements.  Further testing maybe necessary to determine eligibility and will commence 
upon enrollment. These tests are included in Section 9.2 Baseline Assessment.  Some of 
the exams, tests or procedures may be a part of routine care for breast cancer and may be 
used as baseline assessments if conducted no more than 2 weeks prior to participation 
in the study. Other tests are only being done for the purpose of the study. A member of the 
study staff will go over, in detail, with each subject the tests that are being done specifically 
for the study and those that are considered routine care. 
All subjects will receive fulvestrant, but the actual total dose received may vary within 
subjects receiving fulvestrant intraductally, as it is guided by the number of accessible ducts 
and volume of the ducts.  
The first subject of each group will receive intramuscular (IM) fulvestrant (500 mg) and the 
next five subjects of that group will receive intraductal (ID) fulvestrant up to 500 mg. There 
are five groups, for a total of 30 subjects. After fulvestrant instillation, both signs and 
symptoms of local (breast and chest wall) and systemic toxicity will be evaluated using the 
CTCAE v. 5.0.  Each Group – IM; ID, ID, ID, ID, ID. 
 
 
Baseline Assessment (Day -14 to -1) 
Prior to fulvestrant administration, each subject will undergo testing for baseline data 
collection. Any baseline tests performed within 2 weeks prior to study enrollment need not 
be repeated: those data will be considered adequate for baseline evaluation. 
Baseline tests include all of the following: 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
17 
 
• Registration 
• Medical History 
• ECOG performance Status 
• Vital Sign (blood pressure, pulse, respirations, temperature) 
• Digital tumor imaging if a recent digital image is not available 
• Complete blood count with differential and platelet counts (includes hemoglobin, 
hematocrit, platelets and white blood cell count with differential) 
• Chemistry panel (Includes Na+, K+, BUN/Urea, serum Cr, Glu, Alb, AST, ALT, 
Tbili) 
• Pregnancy test (for women of childbearing  potential/pre-menopausal) 
• Concomitant Medications 
• Clinical Breast Assessment 
• Pathological Assessment 
If any of these tests or examinations, reveal criteria rendering the subject ineligible, they 
will be excluded from the study. All subjects must have at least 14-days between 
fulvestrant administration and surgery. 
 
Day of Fulvestrant Administration (Day 0) 
The following procedures should be performed on Day 0 fulvestrant administration: 
• Vital signs (blood pressure, pulse, respirations, temperature) - prior to 
fulvestrant administration 
• PK - Plasma Fulvestrant Level (see Table 1) 
• Pain Assessment (see Section 9.10) 
• Concomitant Medications 
• Adverse Events 
• Pregnancy test of (for women of child-bearing potential/pre-menopausal) 
9.3.1 Intramuscular Administration of Fulvestrant 
The first subject of each of group will be treated with single dose 500 mg of intramuscular 
fulvestrant per the prescribing information, (Appendix 20.3) and can also be found at the 
following website: http://www.azpicentral.com/faslodex/faslodex.pdf#page=1 
 
9.3.2 Intraductal Administration of Fulvestrant 
The second through sixth (2nd through 6th) subject of each of 5 groups will receive 
intraductally administered fulvestrant Jabczenski Ductogram Cannula Microcatheter, the 
IntrocanSafety IV Catheter or other catheter suitable to delivery fulvestrant to the milk ducts.  
Fulvestrant will be infused in up to 5 breast ducts of the breast containing DCIS or invasive 
cancer. Ducts infused with fulvestrant will be marked with sutures. If sutures cannot be 
maintained until mastectomy or lumpectomy, other methods should be employed to mark the 
ducts, as specified in the instruction manual.  At least one photograph of the breast 
documenting infusion location should be taken for the CRF.  Do not instill more than 10 mL 
(500 mg) (i.e., the maximum delivered dose is never to exceed the dose currently in routine 
clinical use for intramuscular delivery). Detailed instructions for intraductal fulvestrant 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
18 
 
administration and use of devices are located in the administration manual provided and will 
be performed on the intraductal fulvestrant subjects only. 
9.3.3 Plasma Drug Concentration Levels 
Subjects will have blood drawn two times on the day of intraductal administration of 
fulvestrant to determine plasma concentration levels. Table 1 lists the sampling schedule 
(below). 
Table 1: PK - Plasma Fulvestrant Level Schedule 
 
PK - Plasma Fulvestrant Level Blood Draw Schedule (Intramuscular and Intraductal) 
Pre-fulvestrant – single blood sample for baseline 
Post fulvestrant administration: 
• 4.5 hours, Subjects are discharged following the 4.5 hour blood collection 
• Day 7 
• Pre-surgery 
 
9.3.4 Post Fulvestrant Administration and Pre-Surgery Assessment 
After fulvestrant administration has been completed, subjects will be assessed for local and 
systemic adverse events during, immediately after and at 30 minutes, 1 hour and 4 hours. As 
noted above, subjects must have at least 14 days between fulvestrant administration and 
surgery, but no longer than 45 days. Pre-operative assessment, as described below, will 
occur before the subject undergoes mastectomy or lumpectomy 14 days following 
intraductal therapy, unless medical condition prohibits operative management. Subjects will 
complete a pain assessment at completion of fulvestrant administration, then at 30 minutes, 1 
hour, and 4.5 hours until discharge from the clinic. Following discharge, the site trial staff 
may assess for AEs by phone. Subjects will be assessed for pain, AE, ECOG performance 
scale (Appendix A), blood drawn per drug schedule and vital signs (blood pressure, 
respiratory rate, pulse, temperature) recorded. See Table 2 to determine daily requirements 
for study procedures. 
Subjects participating in this clinical trial will undergo either a mastectomy or lumpectomy. 
Notwithstanding the unlikely occurrence of an AE that affects the surgery date, participation 
in this trial does not alter the scheduled surgical management of mastectomy/lumpectomy or 
date. In order for subjects to undergo surgery, Atossa recommends but does not require the 
following requirements be met: 
• ECOG performance scale of 0-2 
• Stable vital signs (pulse, blood pressure, respiratory rate and temperature) 
• Adequate organ function as determined by: 
• 
Absolute neutrophil count (ANC) ≥ 1500/μL 
• 
Platelets ≥ 100,000/μL 
• 
Hemoglobin ≥ 9.0 g/dL 
• 
Creatinine ≤ 2 times upper limit of normal 
• 
Bilirubin ≤ 2 times upper limit of normal 
• 
Transaminases (AST/SGOT and ALT/SGPT) ≤ 2.5 times upper limit of 
normal 
The surgeon may elect to postpone the surgery if adverse events may compromise patient 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
19 
 
safety. In the event this occurs, subjects will be treated to abate adverse events prior to 
surgery. They will remain in the clinical trial and be included for analysis.  
 
Days + 1 and + 2 
The following procedures will be performed on Days 1 and 2 post fulvestrant administration. 
Assessment by phone is allowed. 
• 
Collection of concomitant medications 
• 
Adverse event evaluations 
 
Day +7 ± 2 (Day 5 to 9) 
The following procedures will be performed on Day 7 post fulvestrant administration: 
• 
Vital signs (blood pressure, pulse, respirations, temperature) 
• 
PK - Plasma Fulvestrant Level 
• 
Pain assessment (See Section 9.10) 
• 
Collection of concomitant medications 
• 
Adverse Event Evaluations 
 
Pre-Operative (Day 14 + 7) (Day 14 to 21) 
The following procedures will be done prior to surgery: 
• 
ECOG performance status (Appendix 20.1) 
• 
Vital signs (blood pressure, pulse, respirations, temperature) 
• 
Digital tumor imaging 
• 
PK - Plasma Fulvestrant Level 
• 
Complete blood count with differential and platelet counts (includes hemoglobin, 
hematocrit, platelets and white blood cell count with differential) 
• 
Chemistry panel (Includes Na+, K+, BUN/Urea, serum Cr, Glu, Alb, AST, ALT, 
Tbili) 
• 
Pain Assessment (See Appendix 20.2) 
• 
Concomitant Medications 
• 
Adverse Events Evaluation 
• 
Pregnancy test (for women of child-bearing potential) 
 
Day of Surgery (DOS) Day 14 to 45 
No study related procedures will take place during surgery. The surgeon will make every 
effort to maintain the bio-occlusive dressing and nipple markers in the mastectomy 
specimen unless surgical approach would be compromised. These markers are critical for 
pathological handling and processing of the mastectomy specimen to determine any effect of 
drug on treated and untreated ducts.  
Upon complete removal of the mastectomy specimen, colored hydrogels (approximately 1 to 
2ccs) will be injected into the previously treated ducts to allowed focused pathology 
assessment. It will then be sent to pathology for histological examination and tissue sample 
collection. Information regarding pathological assessment is in Section 10.1, Histological 
Assessment. For lumpectomy, this will not be feasible. 
 
Post-Operative/Pre-Discharge (DOS to DOS+D/C) 
Subjects will be assessed according to institutional policy after mastectomy or lumpectomy. 
In addition, subjects will be assessed for AEs, ECOG performance status (Appendix A), and 
vital signs (pulse, blood pressure, respiratory rate, temperature) recorded.  In addition, as 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
20 
 
noted above, blood will be drawn to assess organ function. 
Subjects experiencing any adverse events prior to discharge which may have been caused by 
the study or the study drug, may stay longer in the hospital if indicated or may continue to 
be contacted by their doctor and study doctor. This will be recorded on the CRF. 
In the absence of unresolved AEs that require follow-up after discharge, subject participation 
in this trial will end upon discharge from the hospital. 
The following procedures will be performed post-surgery and before discharge: 
• Vital signs (blood pressure, pulse, respirations, temperature) 
• Concomitant Medications (collection of anesthesia, fluid support or post-
surgical pain management is not required)  
• Adverse Event Evaluation 
• Clinical Breast Assessment 
• Pathological Assessment 
 
Subject Early Discontinuation 
Subjects who discontinue after any fulvestrant administration on Day 0 will complete the 
following procedures. 
• Concomitant Medications 
• Adverse Events Evaluation 
• Reason(s) for discontinuation 
• Pregnancy test (for woman of child-bearing potential) 
If a subject is withdrawn or discontinues study participation, reasonable efforts will be made 
to complete the final study procedures. The subject will continue to be followed and 
medically managed in accordance with the arrangement that was in place prior to study 
enrollment. 
 
 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
21 
 
Table 2: Schedule of Assessments 
 
Timeline 
Baseline 
Fulvestrant 
Administration 
Post 
Administration 
Pre- 
Op 
Day of 
Surgery 
Day of 
Discharge12 
Early  
Discontinu-
ation 
Day 
Procedures 
-14 to -1 
0 
1 and 2 
7 (±2) 
14 - 21 
DOS 
(Day  
14 to 45) 
DOS +  
Post 
fulvestrant 
administratio
Informed Consent 
X 
 
 
 
 
 
 
 
Registration 
X 
 
 
 
 
 
 
 
Physical Exam 
X 
 
 
 
X 
 
 
 
Medical History 
X 
 
 
 
 
 
 
 
ECOG Performance Status 
X 
 
 
 
X 
 
 
 
Vital Signs1 
X 
X2 
 
X 
X 
 
X 
 
Digital tumor imaging if needed 
X 
 
 
 
X 
 
 
 
PK - Plasma Fulvestrant Level 
 
X3 
 
X 
X 
 
 
 
CBC with Diff & Platelets4 
X 
 
 
 
X 
 
 
 
Chemistry panel5 
X 
 
 
 
X 
 
 
 
Pregnancy Test10 
X 
X 
 
 
X 
 
 
X 
Pain Assessment 
 
X6 
 
X 
X 
 
 
 
Fulvestrant administration 
 
X 
 
 
 
 
 
 
Concomitant Medications 
X 
X 
X7 
X 
X 
 
X8 
X7 
Adverse Event Evaluation 
 
X9 
X7 
X 
X 
 
X 
X7 
Clinical Breast Assessment 
X 
 
 
 
 
 
X 
 
Pathological Assessment11 
X 
 
 
 
 
 
X 
 
Reason(s) for Discontinuation 
 
 
 
 
 
 
 
X 
1 
Blood pressure, pulse, respiration,  temperature 
2 
Prior to fulvestrant administration 
3 
On Day 0/fulvestrant administration, PK plasma samples are obtained pre-fulvestrant administration, and 4.5 hours 
post administration (see Table 1) 
4 
Includes hemoglobin, hematocrit, platelets and white blood cell count with differential 
5 
Includes Na+, K+, BUN/Urea, serum Cr, Glu, Alb, AST, ALT, Tbili 
6 
On Day 0/fulvestrant administration Pain Assessment completed prior to fulvestrant administration/nipple preparation 
(Intraductal only), Post Nipple Anesthesia (Intraductal only), at completion of fulvestrant administration, 30 minute, 1 
and 4.5 hours post administration. (see Section 9.10) 
7 
Assessment by phone is allowed 
8 
Collection of anesthesia, fluid support or post-surgical pain management is not required 
9 
Assess adverse events during fulvestrant administration, immediately after administration, at 30 minutes, 1 hour and 4 
hours 
10 Only women of childbearing potential are tested at baseline or thereafter 
11 Includes tissue sample collection for fulvestrant concentration 
12 Participation in the trial concludes upon discharge from the hospital 
 
 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
22 
 
 
Supportive Care 
No other anti-estrogen medication is allowed during the study, and no estrogen therapy 
within 30 days prior to fulvestrant administration. Otherwise, concomitant medications and 
therapies deemed necessary for the supportive care and safety of the subject are allowed, 
provided their use is documented in the medical records and CRF. Collection of anesthesia 
during surgery, fluid support or post-surgical pain management is not required. Supportive 
care is provided as guided by institutional standards of care. 
 
Pain Assessment 
Obtain Pain Assessment (see Appendix B), minimally, according to the following schedule 
 
Visit 
Collection Time 
Day of Fulvestrant 
Administration (Day 0) 
• 
Prior to fulvestrant administration and prior to nipple 
preparation for intraductal subjects 
• 
Post Nipple Anesthetic (Intraductal Subjects Only) 
• 
At completion of fulvestrant administration/instillation 
• 
30 minutes post administration 
• 
1 hour post administration 
• 
4.5 hours post administration 
Day +7±2 
Any time during visit 
Pre-Operative (Day 14 ± 7) 
Any time during visit 
 
If, during intraductal fulvestrant infusion, the subject reports Grade 3 or 4 pain (CTCAE 
criteria) in the breast which does not resolve within 10 minutes after infusion of the drug, 
treatment of additional ducts will be discontinued. Blood draws and follow-up assessment as 
well as pathological assessment as described in Section 10.1 will be performed per the 
protocol. 
 
Description of Medical Devices (for intraductal fulvestrant use only) 
9.12.1 Name of Medical Devices 
The FullCYTE® Breast Aspirator and either:  
• Jabczenski Ductogram Cannula – G04303 –or most current item number (Cook 
Medical); or  
• IntrocanSafety IV Catheter 24G x 0.55 FEP, Winged, Notched (B Braun) 
• An alternative catheter may be used to facilitate drug delivery.    
 
9.12.2 Indications for Use of the Medical Devices 
The FullCYTE Breast Aspirator device may be used to identify ductal orifices for 
subsequent cannulation with the FullCYTE Breast MicroCatheter. 
 
The Site may also use a Jabczenski Ductogram Cannula Microcatheter, the Intracan Safety 
Catheter or another analogous device that facilitates drug instillation into the milk ducts. 
Detailed instructions for intraductal fulvestrant administration and use of devices is located in 
the administration manual. 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
23 
 
9.12.3 Description of the Investigational Medical Device 
The FullCYTE Breast Aspirator is supplied and manufactured by Atossa Genetics, Inc., 
using Good Manufacturing Practices (GMP) and following all regulations.  Sterile 
microcatheters sufficient to intraductally instill fulvestrant will be obtained from acceptable 
suppliers.  Preferred devices include the:  
• Jabczenski Ductogram Cannula – G04303 –or most current item number (Cook Medical)  
• IntrocanSafety IV Catheter 24G x 0.55 FEP, Winged, Notched (B Braun). 
The FullCYTE Breast Aspirator (F-450-02) device is similar to non-powered breast 
pumps used to express milk from lactating women. The device is comprised of a rigid 
polycarbonate cup with an adhesive foam liner used to secure placement around the breast 
nipple. The polycarbonate cup is attached to a user supplied standard syringe, which is 
used to pull a gentle vacuum to express breast ductal fluid. The FullCYTE Breast Aspirator 
device is provided non-sterile and is intended for single patient use only. The Breast 
Aspirator is packaged in a sealed bag. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
24 
 
 
MicroCatheters 
Jabczenski Ductogram Cannula 
 
 
 
Introcan Safety Catheter 24G x 0.55 FEP, Winged, Notched 
 
Refer to the information provided by the manufacturer. 
 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
25 
 
9.13.1 Storage and Handling and Stability 
Store in a cool dry place. See the The FullCYTE Breast Aspirator and microcatheters have 
expiration dates provided on the device labels. 
9.13.2 Device Dispensing 
Fulvestrant will be infused in up to five breast ducts. A minimum of five catheters should be 
dispensed for each subject receiving intraductal fulvestrant administration.  
9.12.3 Description of Investigational Product 
Fulvestrant will be procured by the hospital pharmacy. The full prescribing information is 
provided in Appendix 20.3 and can be found at:  
http://www.azpicentral.com/faslodex/faslodex.pdf#page=1 
 
10.0 
ASSESSMENT OF EFFICACY 
While the primary objective of this study is safety and tolerability, efficacy parameters are 
Ki67 ER/PgR expression and tumor size by digital imagery, preferably by mammography. 
 
Pathological Assessment 
The clinic pathologist will conduct the pathologic examinations per institutional standards. 
Additional instructions are provided by the Sponsor.  
The purpose of pathological examination is to provide objective assessment of local effect 
of fulvestrant on nipple skin, ductal cells (benign and malignant), and surrounding 
fibroadipose tissues. Specifically, the effect of fulvestrant on cell death (apoptosis and 
necrosis), proliferation (mitosis), and inflammatory reaction will be examined. 
Mastectomy or lumpectomy specimens will be received and processed at the site’s 
laboratory after intramuscular or intraductal therapy per institutional standards. Additional 
instructions are provided by the Sponsor, to include examination of the tissue for 
pathological evidence of response. Specific attention will be paid to identify the cannulated 
ducts. Aided by the colored Hydrogel of  mastectomy specimens, the ducts identified in the 
breast parenchyma will be correlated with duct openings identified on the nipple (with 
suture), and compare the cannulated ducts (areas) with non- cannulated ducts (areas) for cell 
death, proliferation, and inflammatory response, as examined using routine hematoxylin 
and eosin (HE) sections. It is assumed that in most subjects, not every duct will be 
identified or accessed and in these cases those ducts which are not cannulated will be 
compared to the ones that were cannulated from a histological stand point. Samples will be 
stored per site’s standard procedures. 
A mastectomy or lumpectomy specimen will be dissected and samples taken to measure 
tissue fulvestrant levels.  
 
Plasma Drug Concentration Levels 
Subjects will have blood drawn several times (see Table 1) to determine plasma 
concentration levels pre- and post-fulvestrant administration. The blood processing procedure 
is provided in the lab manual. 
10.2.1 Fulvestrant PK Analysis 
Plasma and tissue concentrations will be determined per the described methodology in the 
PK report and referencing prior publications.30 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
26 
 
 
Dose Limiting Toxicity 
If Dose Limiting Toxicities (DLT) are identified meeting the definition set forth below, the 
dose in subsequent subjects will be lowered to no more than 250 mg total (5 mL).  DLT will 
include any study-drug related grade 5 toxicity (death).  In addition, if 20% or more (≥ 6 
subjects) exhibit a single study drug-related Grade 3 or 4 adverse event (AE) per the 
CTCAE or SAE as defined in Section 11.2.3, the dose in subsequent subjects will be reduced 
to 250 mg. SAE Definition in the following categories: blood/bone marrow, cardiac, general 
constitutional symptoms, dermatology/skin, gastrointestinal, thrombo-embolic, 
hemorrhage/bleeding, infection, metabolic/laboratory, musculoskeletal/soft tissue, 
neurology, pain, pulmonary, upper respiratory, renal/genitourinary, or vascular this will be 
considered DLT and the study drug dose lowered for subsequent subjects. Additionally, if 
50% or more subjects (≥ 15 subjects), experience greater than 5 study related Grade 2 AE, 
this will be considered DLT and the study drug dose in subsequent subjects be lowered to 
250 mg. Subjects who experience an allergic reaction, including anaphylaxis, to the dyes or 
drugs in this study will not be considered a DLT.  
11.0 
ASSESSMENT OF SAFETY 
This trial will use the descriptions and grading scales from the CTCAE v. 5.0 of the NCI for 
adverse event reporting. Information about all adverse events (AE), regardless of source 
(self- reported by subject, reported by questionnaire, collected through examination, 
laboratory or imaging) will be recorded in the medical record as well as CRF. The section 
below describes the procedures for collecting and reporting AE. 
 
Procedures in Case of Emergency 
The investigator is responsible for assuring that equipment, procedures and personnel with 
the expertise to manage medical emergencies are in place throughout the course of the study. 
An emergency may constitute a serious adverse event (SAE), see Section 11.2.3 SAE 
Definition.  In such case, the procedures outlined in Section 11.2.6 Procedures for Adverse 
Event Reporting for the should be followed. 
 
Safety Monitoring and Reporting 
11.2.1 Adverse Events 
Both signs and symptoms of local (breast and chest wall) and systemic toxicity will be 
evaluated.   
The most common side effects of fulvestrant when given into the muscle in the buttocks, 
reported from previous studies and after marketing, include: 
• nausea (14%) 
• injection site pain (12%) 
• back pain (11%) 
• bone pain (9%) 
• headache (8%) 
• joint pain (8%) 
• pain in extremities (7%) 
• hot flash (7%) 
• weakness (6%) 
• vomiting (6%) 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
27 
 
• loss of appetite (6%) 
• muscle pain (6%) 
• constipation (5%) 
• cough (5%) 
• shortness of breath (5%)  
 
Increased liver enzymes (which may indicate liver damage) and allergic reaction may also 
occur, but in less than 5% of patients who receive the drug. 
All of the side effects listed above may occur, but may or may not be the same in severity or 
frequency when fulvestrant is injected into the breast. 
 
There are additional possible discomforts or risks from administration into the breast, as that 
process includes administration of anesthetic, breast duct identification using the aspirator, 
catheter placement and fulvestrant injection. These additional risks include: 
• injury to the milk duct 
• bleeding and bruising 
• infection 
• breast pain, discomfort or inflammation 
• allergic reaction to the anesthetic, dyes, or the study drug, fulvestrant, used in this 
study. 
 
11.2.2 Adverse Event (AE) Definition 
An adverse event (AE) is defined by the NCI as any unfavorable symptom, sign, or 
disease (including an abnormal laboratory finding) associated with the use of a medical 
treatment, device or procedure that may or may not be considered related to or caused 
by the medical treatment or procedure. An AE also includes any newly occurring event or 
previous condition that has increased in severity or frequency since the initiation of the 
investigational procedures or administration of the investigational drug or device. 
Assessment of the occurrence of an AE will be based on changes in the subject’s 
laboratory results and/or signs and symptoms. AEs will be monitored until they are resolved 
or clearly determined to be due to a subject’s stable or chronic condition or concurrent 
illness (es). Medical care will be provided, as defined in the informed consent, for any AE. 
Collect all Adverse Events on the Adverse Event (AE) CRF and the MedWatch 3500 form. 
There are two types of adverse events, expected and unexpected. It is expected that subjects 
may feel slight minimal discomfort during the study procedures and post-procedure; both 
events are considered self-limiting. It is further expected that subjects will experience post-
operative discomfort after surgery. This will be treated according to routine institution and 
clinician routine. Subjects who experience any untoward or unexpected after-effects 
following the study procedures, blood collection or surgery are instructed to contact the 
Principal Investigator or study coordinator immediately. 
All AEs, regardless of intensity or causal relationship, are to be recorded in the CRF and 
source documentation. The investigator must determine both the intensity of the AE and the 
event’s relationship to study product administration. Unexpected events such as excessive 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
28 
 
discomfort or prolonged breast pain following the procedure, infection, persistent discharge, 
or any other condition reported by the subject and treated by a physician should be reported 
on the AE CRF. 
11.2.3 AE Intensity Classification 
Intensity will be defined according to the following CTCAE criteria: 
Grade 
Definition 
1 
Mild AE 
2 
Moderate AE 
3 
Severe and undesirable AE 
4 
Life-threatening or disabling AE 
5 
Death related to AE 
 
 
11.2.4 AE Relationship Classification 
Assess the relationship to study interventions (investigational product or device) as follows: 
Relationship 
Attribution 
Description 
Unrelated to 
investigational 
agent/intervention 
Unrelated 
The AE is clearly NOT related to the intervention 
Unlikely 
The AE is doubtfully related to the intervention 
Related to 
investigational 
agent/intervention 
Possible 
The AE may be related to the intervention 
Probable 
The AE is likely related to the intervention 
Definite 
The AE is clearly related to the intervention 
11.2.5 SAE Definition 
An SAE is any untoward medical occurrence that is a prolonged Grade 3 AE or any Grade 4 
or 5 event as defined above or: 
• Results in death 
• Is life threatening (refers to an event in which the subject was at immediate risk 
of death at the time of the event; it does not refer to an even which 
hypothetically might have caused death if it were more severe) 
• New or prolongs existing hospitalization 
• Results in persistent or significant disability/incapacity 
• Is a congenital anomaly/birth defect 
• Requires intervention to prevent permanent impairment/damage (Devices only) 
A medical event that may not be immediately life threatening or result in death or 
hospitalization but may jeopardize the subject or may require intervention to prevent a 
serious outcome may also be considered serious. Medical and scientific judgment must be 
exercised when classifying events as serious. 
A distinction must be drawn between SAEs and severe AEs. A severe adverse event is a 
major event of its type. A severe adverse event need not necessarily be considered serious. 
For example, nausea, which persists for several hours, may be considered severe nausea but 
does not fulfill the criteria for an SAE. Alternatively, a stroke, which results in only a 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
29 
 
limited degree of disability, may be considered to be a mild stroke but would fulfill the 
criteria for an SAE. 
Monitor all SAEs until the event is considered resolved. 
All SAEs, regardless of relationship to study procedures, must be reported to the study 
medical monitor and reported according to the procedures outlined in Section 7.2.6 11.2.6 
Procedures for Adverse Event Reporting. 
11.2.6 Procedures for Adverse Event Reporting 
An adverse event that fulfills any one or more of the criteria in Section 11.2.5 SAE 
Definition must be reported as an SAE according to the following guidelines: 
The investigator must inform the Atossa medical monitor within 24 hours of learning of 
event by telephone, text or fax of any SAE which occurs during the course of each 
subject’s study participation (e.g., from enrollment through study termination), whether or 
not considered causally related to the study procedure. 
 
Sponsor SAE Contact Information 
Primary 
Steven Quay, MD, PhD 
CEO & President, Atossa Genetics, Inc.  
e-mail: safety@atossagenetics.com  
e-mail: Steven.Quay@atossagenetics.com 
Mobile: 206-419-4873 
Back-up  
Janet R Rea, MSPH 
SVP, Regulatory, Quality & Clinical Affairs 
Mobile: 206-799-7186 
Mobile: 206-550-0226 
janet.rea@atossagenetics.com 
 
 
An unanticipated adverse event [as defined in 21 CFR 312] is any serious adverse effect 
on health or safety or any life-threatening problem or death caused by or associated with the 
study intervention, it that effect, problem, or death was not previously identified in nature, 
severity, or degree of incidence in the investigational plan or application, or any other 
unanticipated serious problem that relates to the rights, safety, or welfare of subjects. 
SAEs will be reported to appropriate regulatory authorities by Atossa Genetics according 
to all applicable regulatory requirements for documentation and reporting of SAE (21 CFR 
312). It is the responsibility of the investigator to promptly notify the IRB of all 
unanticipated problems involving risk to human subjects. 
Adverse events classified as expected or unexpected will be tabulated and analyzed at 
the conclusion of the study. For adverse events that are breast specific, the unit of tabulation 
will be the breast. For adverse events that do not relate to the breast, the unit of tabulation 
will be the subject. All subjects who have received intraductal administration will be 
included in the safety analyses for adverse event reporting. All adverse events reported 
during this study will be listed with the grade, severity, relationship to study intervention, 
outcome, and action taken. 
Should a pregnancy occur, it must be reported and recorded on the pregnancy form. 
Pregnancy itself, is not regarded as an AE unless there is a suspicion that an investigational 
product may have interfered with the effectiveness of a contraceptive medication. 
The outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
30 
 
or congenital abnormality) must be followed up and documented even if the patient was 
discontinued from the study. 
All reports of congenital abnormalities/birth defects are SAEs. Spontaneous miscarriages 
should also be reported and handled as SAEs. Elective abortions without complications 
should not be handled as AEs. 
12.0 
ACCOUNTABILITY, RISKS AND BENEFITS 
 
Accountability 
Accurate records must be maintained for all investigational devices received, dispensed, and 
returned or destroyed. The study drug, fulvestrant, will be purchased by the hospital 
pharmacy. The allocation and administration of study drug to the study participants must be 
fully and contemporaneously recorded. The site will maintain study drug,  FullCYTE Breast 
Aspirator and Microcatheter supplies accountability during the study on accountability logs 
provided by the sponsor (or the site’s form is acceptable and if the following information is 
collected: the identification of the subject to whom the drug or microcatheters were 
dispensed and the date, lot number and quantity of the drug dispensed to the subject. Unused 
study supplies will be returned to the Sponsor. The Sponsor or designee will conduct drug 
accountability during the course of the study and at site closeout. Disposition of unused 
study drug will be handled according to institutional standards. The Sponsor or designee will 
conduct final study supplies accountability at site closure. 
13.0 
STATISTICS 
The primary aim of this study is to assess safety and tolerability in subjects receiving 
intraductal fulvestrant. In addition, this trial aims to characterize the PK of this alternative 
route of administration, and compare the intraductal PK profile to that of  standard 
intramuscular administration. A pharmacokinetic population analysis will be used to 
characterize biodiversity in exposure and alternative route absorption rate. 
Additional analyses not described in the sections below may be specified in a Statistical 
Analysis Plan. A detailed Statistical Analysis Plan will be done prior to database lock. 
 
 
Adverse Events Analysis 
All serious adverse events will be reported. All non-serious AEs occurring in at least 10% 
of the subjects will similarly be reported. 
 
Sample Size and Statistical Analyses 
A total of 30 subjects who are undergoing mastectomy or lumpectomy will be included in this 
study: 6 will receive intramuscular, and 24 will receive intraductal fulvestrant. With respect 
to the sample size for the latter group with 24 subjects, it will be possible to detect an effect 
size of approximately 0.60 with 80% power and 0.69 with 90% power. Both of these are in 
the medium to large range according to Cohen’s terminology and are based on the 
demonstration of a reduction in the Ki67 labeling index mean from baseline (diagnostic 
biopsy) to week 4 (surgically excised specimen) using a paired t-test. With these effect sizes 
and an anticipated 50% decline in the mean index, then the expectation would be a standard 
deviation in this reduction of about ±83.7% for 80% power and ±72.3% for 90% power. 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
31 
 
The primary endpoint of this study is to assess safety and tolerability as measured by adverse 
events, subject pain assessment as well as signs of topical irritation seen on the excised 
specimen. In addition, the effect of the administration will be evaluated with respect to the 
change in Ki67 labeling index (primary efficacy endpoint) and changes in estrogen and 
progesterone receptor expression (secondary efficacy endpoints) 
Descriptive statistics will be used to summarize the data (means/medians and standard 
deviations/interquartile ranges for quantitative data and proportions/percentages for 
categorical data such as adverse events), and numerically compare the groups with entry 
diagnoses of invasive ductal carcinoma and DCIS, respectively. In addition, the 6 study 
subjects who receive intramuscular fulvestrant will be qualitatively compared with the main 
study cohort of 24 subjects who receive intraductal fulvestrant. 
The primary analysis of the change in Ki67 labeling index will be compared between the two 
time points (baseline or time of diagnostic biopsy versus 4 weeks or time of the surgically 
excised specimen collection) using the paired t-test (assuming normality of the differences) 
or the Wilcoxon signed rank test if normality cannot be demonstrated or a transformation to 
normality using the Box-Cox family of power transformations cannot be used. A similar 
analysis will be employed to evaluate the secondary endpoint of changes in mean estrogen 
receptor and progesterone receptor expression. In addition, 95% confidence intervals for the 
mean difference for these variables between the two time points will be computed using the 
t-statistic or a rank statistic as required by the distribution of the study data. 
The results for the efficacy endpoints will be compared in a descriptive fashion with those 
seen by Kuter et al (Kuter I, Gee JMW, Hegg R et al): Dose-dependent change in biomarkers 
during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized 
Phase II study. Breast Cancer Res Treat 133: 237-246, 2012. 
 
 
Plasma Concentration Levels 
The statistical analysis used for the pharmacokinetic (PK) population study may employ one 
or more of several advanced analysis packages including WinNonlin, Kinetica, Matlab, or R. 
For each subject, plasma level time curves will be assessed individually for the absorption 
rate and body compartment parameters. Both a one compartment and a two-compartment 
model will be considered. The literature values will be used for the initial conditions of 
the body compartment parameters, and a weighted nonlinear routine will be used for the 
parameter estimation. The optimal model will be chosen based on the Akaike 
Information Criterion (AIC). 
Equation 2. PK Model Selection Criterion 
AIC = N* ln (SSQ) + 2p 
Here, N is the number of samples, ln(SSQ) is the natural logarithm of the sum of the 
squared residues, and p is the number of model parameters. The model yielding the lowest 
AIC will be chosen. 
Secondarily, standard parameters such as mass, body surface area, and body mass index will 
be assessed to determine if their inclusion will improve a joint parameter estimation 
using all subjects tested for a given agent dose. In the case that dosing for an agent was 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
32 
 
terminated due to high AE, then such analyses will only be performed if sufficient subjects 
are available. 
Standard PK parameters will then be calculated as appropriate to the modeling form (one 
or two compartmental model). 
Differences between the absorption rate parameters and standard PK parameters will be 
assessed. 
It is recognized that in some subjects, surgery may have already occurred before plasma Cmax 
is reached. 
13.4 Tissue Concentration 
The fulvestrant concentration in the breast tissue will be determined from the specimen 
obtained during the pathology examination of the tissue excised during surgery. 
 
14.0 
DIRECT ACCESS TO SOURCE DATA/DOCUMENTS 
The investigator is responsible for maintaining any original source data documentation 
related to the study, the subject identification list and all original signed informed consent 
form(s) as outlined in Section 17.6, Record Retention. Study-specific CRFs must be 
completed for each subject enrolled in the study as outlined in Section 17.1, Recording of 
Data. 
 
Access to Source Documents 
Atossa Genetics is responsible for assuring that the data collected is complete and accurate. 
The most effective way to assure the accuracy of the data is to review individual subject 
records and other supporting documents and compare those records with the reports 
prepared by the investigator for submission to the sponsor. Therefore, during a periodic 
visit, the monitor will compare a representative number of subject records and other 
supporting documents with the investigator’s reports to determine that: 
• The information recorded in the investigator’s report is complete, accurate and 
legible. 
• There are no omissions in the reports of specific data elements such as the 
administration to any subject of concomitant study drug or the development of an 
intercurrent illness. 
• Missing visits or examination are noted in the reports. 
• Subjects failing to complete the study and the reason for each failure are noted in 
the reports. 
• There is no evidence of fraud or data falsification. 
 
Monitoring 
In accordance with regulatory guidelines as outlined in 21 CFR 312, the sponsor is 
required to monitor the progress of a clinical investigation. Proper monitoring is necessary to 
assure adequate protection of the rights of human subjects, the safety of all subjects involved 
in clinical investigations, and the quality and integrity of the data. 
Following the conduct of the study initiation visit, Atossa or its representatives (e.g., CRA 
or representative contracted to support this clinical trial) may attend and observe some of the 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
33 
 
study related intraductal procedures and data collection at the institution to ensure proper 
conduct of the study. The investigator will permit all CRA to monitor the study as frequently 
as the CRA deems necessary in order to ensure that the clinical facilities remain 
acceptable and that data recording and protocol adherence remain satisfactory.  The CRFs 
and related source documents will be reviewed per the monitoring plan. This includes tests 
performed as a requirement of participation in the study (e.g., history, intraductal 
administration of any agent, imaging, pathology, and reports) and may include other medical 
records required to confirm the information contained in the CRFs. 
During the review of these documents the anonymity of the study subject will be 
maintained with strict adherence to professional standards of conduct/and confidentiality. 
Prior to each monitoring visit, the investigator should record all data generated since the last 
visit in each subject’s CRFs. The investigator and staff will be expected to cooperate with 
the CRA, to be available during at least a portion of the monitoring visit to answer questions, 
and to make corrections and provide missing information as is deemed necessary. 
The CRA will record the date of each visit in the Monitor Sign-In Log and will document 
all findings and a summary of the study status and progress in a monitoring report. Any 
proposed actions will be discussed with the investigator and will be confirmed in writing. 
 
Written Monitoring Procedures 
Written procedures for monitoring clinical investigations will be followed to assure the 
quality of the study and to assure that each person involved in the monitoring process carries 
out his or her duties. 
 
Monitoring Visits 
The schedule of monitoring visits will be detailed in the monitoring plan. 
 
Audits and Inspections 
Authorized representatives of Atossa or a regulatory agency, may visit the site to perform 
audits or inspections, including source data verification. The purpose of an Atossa audit or 
inspection is to systematically and independently examine all study-related activities and 
documents to determine whether these activities were conducted, and data were recorded, 
analyzed, and accurately reported according to the protocol, Good Clinical Practice 
guidelines of the International Conference on Harmonization, and any applicable regulatory 
requirements. The investigator should promptly contact the Atossa representative if 
contacted by a regulatory agency about an inspection. 
15.0 
QUALITY CONTROL AND QUALITY ASSURANCE 
 
Investigator Selection 
Prior to the initiation of the clinical trial, the investigator and any co-investigators must 
provide Atossa with copies of their current licensure and curriculum vitae, including a list of 
publications and any other relevant documentation requested by the sponsor, the 
Institutional Review Board (IRB) and/or regulatory agencies. 
The investigator (s) shall meet all the qualifications specified by the applicable regulatory 
requirement (s) of Title 21 Code of Federal Regulations (CFR) Part 312.53, shall provide 
evidence of such qualifications, and shall be qualified by the sponsor based upon: 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
34 
 
• Education 
• Training and experience to assume responsibility for the proper conduct of the trial 
• Professional standing and experience (including licensure) 
• Professional referrals 
• Authors of pertinent publications 
• Investigator workload 
• Adequate access to study population 
In addition to investigator qualifications, institutions must meet the following criteria: 
• Experience in conducting clinical trials 
• Adequate access to study population(s) 
• Qualifications and availability of study site personnel 
• Adequate equipment and facilities to conduct clinical trial procedures 
 
Changes to the Protocol and Study Related Procedures 
No change in the study protocol or any study related procedure may be implemented 
without the mutual, written agreement of the investigator and the medical monitor of Atossa. 
All changes must be documented by signed protocol amendments that are agreed to and 
signed by Atossa; copies provided to the IRB/IEC; and the IC revised if necessary. Trial 
participants may need to be re-consented depending on the nature of any protocol 
amendments. 
It is the responsibility of Atossa to distribute any proposed amendment to the investigator at 
each clinical site. The investigator is responsible for the distribution of any amendments to 
all relevant staff concerned with the conduct of the study at the study site, as well as to the 
IRB. 
 
Study Termination by the Sponsor  
The Sponsor reserves the right to prematurely terminate the study if, in the opinion of the 
sponsor, there is sufficient reasonable cause. Sponsor will make every effort to provide 
30-days written notice of study termination, except when the reason for termination 
concerns subject safety, in which case the clinical trial may be discontinued immediately. 
Written notification documenting the reason for such a termination will be provided to the 
investigators. Circumstances that may warrant termination include, but are not limited to: 
• Determination of unexpected, significant or unacceptable risk to the subjects 
• Overall failure to enroll study subjects at an acceptable rate 
• Plans to modify, suspend or discontinue the development of the study 
product/procedure 
 
Site Termination by the Sponsor 
Sponsor has the right to terminate an individual study site and remove all study materials 
from a site at any time. Reasons for termination of a study site may include, but are not 
limited to the following: 
• It is apparent that subject enrollment is unsatisfactory with respect to quality 
and/or quantity of potential study subjects 
• Data recording is inaccurate and/or incomplete on a consistent basis 
• Insufficient adherence to protocol requirements 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
35 
 
• Inadequate informed consent of study subjects 
• Integrity of data is questionable or unable to be verified 
• Preliminary data/outcomes at this study center indicate that the study product 
poses an unacceptable risk/health hazard to study participants. 
• Consistent failure to adhere to GCPs. 
 
Good Clinical Practices 
This study will be conducted in accordance with International Conference on 
Harmonization, (ICH) Guidelines for GCPs and the appropriate regulatory requirement(s) of 
Title 21 CFR Parts 11, 50, 54, 56, 312 and 314, with the overall purpose of ensuring the 
safety and well-being of the participating trial subjects. The investigator will be thoroughly 
familiar with the appropriate use of the study product(s) and procedure(s) as described in this 
protocol. Essential clinical documents will be maintained to demonstrate the validity of the 
study and the integrity of the data collected. Master files will be established at the beginning 
of the study, maintained for the duration of the trial and retained according to the 
requirements outlined in this protocol and all appropriate regulations. 
 
Protocol Compliance 
The investigator will conduct the trial in compliance with the protocol and after 
approval/favorable opinion by the IRB and the appropriate regulatory authority(ies). 
Modifications to the protocol should not be made without agreement of both the 
investigator(s) and the sponsor. Changes to the protocol will require written IRB 
approval/favorable opinion prior to implementation, except when the modification is needed 
to eliminate an immediate hazard(s) to subjects or if the change(s) involves   only 
logistical or administrative aspects of the trial. The IRB may provide, if applicable 
regulatory authority(ies) permit expedited review and approval/favorable opinion for minor 
change(s) in ongoing trials that have the approval of the IRB. 
When immediate deviation from the protocol is required, the investigator will contact the 
medical monitor, if the circumstances permit, to discuss the planned course of action. Any 
departures from the protocol must be fully documented in the CRFs and source 
documentation. 
 
16.0 
ETHICS 
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki 1989 and in compliance with 45 CFR part 46 and are consistent with 
ICH Good Clinical Practice, and applicable regulatory requirements. 
In order to safeguard the rights, safety and wellbeing of the subjects in this study, the 
study protocol, subject information, subject informed consent form (ICF), and copies of any 
proposed advertisements to be used (if applicable), must be reviewed and receive the 
approval of an IRB/IEC.  The opinion and notification of approval by the IRB should be 
given in writing and should refer to this study by title, version date and study number. In 
addition, a list of those present at the IRB meeting, with their positions and institutional 
affiliations clearly stated, should be attached whenever possible. 
It is the responsibility of each investigator to forward a copy of the notification of IRB 
approval for both the protocol and the subject ICF to Atossa prior to the start of study 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
36 
 
enrollment at each study center when multiple centers participate. 
The investigator will also ensure that all changes in the approved research activities, and 
all unanticipated problems involving risks to the subjects in the study are promptly reported 
to the IRB; and that no changes will be made to the protocol without IRB approval, 
except when necessary to eliminate apparent immediate hazards to the subject. For minor 
changes to previously approved research, it may be possible for the investigator to secure an 
expedited review by the IRB as provided for under 21 CFR Part 56.110. 
As part of the IRB requirement for continuing review of approved research, the investigator 
will be responsible for submitting periodic progress reports to the IRB at intervals 
appropriate to the degree of subject risk involved, but no less than annually. All 
correspondence to and from the IRB should be filed by the investigator in the study specific 
regulatory files. Copies of all such correspondence as well as notification of continued IRB 
approval of this trial, or withdrawal of such approval, must immediately be forwarded to 
Atossa by the study investigator. 
All safety updates, annual progress reports and any revisions to the aforementioned 
documents will be provided to the IRB by the investigator. No change in study conduct 
will be made without the prior written approval of the IRB. 
The investigator acknowledges that his/her institutional approval to conduct this clinical trial 
is limited to the site of investigation specified in the submission to the reviewing IRB. 
 
Subject Information and Informed Consent 
In accordance with guidelines as outlined in CFR 21 Part 50, the investigator will ensure that 
the subject or the subject’s legal representative (as appropriate) are provided full and adequate 
verbal and written information about the nature, purpose, possible risks and benefits of this 
study. They must also be notified that they are free to discontinue their participation in this 
study at any time. The subject will not be entered into the trial nor will any non-routine 
procedures be performed prior to obtaining written informed consent from the subject. 
The subject and/or the subject’s legal representative should retain a copy of the signed ICF. 
Should modifications be made to the current ICF, the revised IRB approved version of the 
ICF must be signed by the subject and or the subject’s legal representative prior to the 
institution of any proposed change in study conduct. The ICF outlines the procedures and 
requirements associated with participation in this clinical trial. 
17.0 
DATA HANDLING AND RECORD KEEPING 
 
Recording of Data 
All required data will be recorded on CRFs for each subject. It is the investigator’s 
responsibility to ensure the accuracy, completeness, legibility and timeliness of the data 
reported in the subject’s CRFs. Source documentation supporting the CRF data should 
reflect the subject’s participation in the trial and should document the dates and details of 
study procedures, AEs and subject status. 
For every study subject, the subject/medical record notes should clearly indicate at least the 
following: 
• That the subject is/was a participant in the study (via subject and study 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
37 
 
identification) 
• All therapies and medications 
• All visits to the physician’s office/hospital, including those that were for study 
purposes only 
• All AEs and SAEs, if applicable 
All fields on each subject’s CRF must be completed, and any missing data or discrepancies 
must be explained. 
 
Financing and Insurance 
The Sponsor is responsible for funding the study, and will provide insurance coverage 
adequate to cover each subject. Insurance will be in place prior to starting the study. 
 
Data Collection Requirements 
Upon enrollment, each subject will be provided a unique Subject ID number. A Data 
Management Plan (DMP) will be developed and will define all data management issues for 
the clinical trial from database design development and validation to data management 
handling of documents. All data entry personnel will be trained to the appropriate sections of 
the DMP prior to involvement in the clinical trial. 
All data obtained during the clinical trial will be recorded on CRFs for each subject. 
Data entry personnel will then verify all data. All CRF data will be verified by Atossa and 
tracked by an audit trail documenting the following: 
• Clinical Data Entry Assistant 
• Date of Entry 
• Value of data changes 
• Date of data changes 
The clinical trial database will include logic checks for applicable fields to further ensure 
data integrity. If necessary, the clinical sites will be contacted for data corrections or 
clarifications via faxed quality control reports. 
 
Subject Data Protection 
In order to maintain subject privacy, all CRFs, study reports and communications will 
identify the subject by the assigned subject ID number only. The investigator will grant 
monitor(s) and auditor(s) from the sponsor or designated contract research organization(s), 
the IRB and regulatory authority (ies) access to the subject’s original medical records for 
verification of data entered on the CRFs and to audit the data collection process. The 
subject’s confidentiality will be maintained and will not be made publicly available to the 
extent permitted by the applicable laws and regulations. 
As part of the informed consent process, the subject and/or her legal representative will be 
informed in writing about the possibility of audits by authorized representatives of the 
sponsor and/or regulatory authorities, in which case a review of those parts of the medical 
records relevant to the study may be required. The subject and or their legal representative 
will also be informed in writing that every effort to protect subject’s confidentiality will be 
maintained. 
The investigator is responsible for maintaining a list of all study subjects who have been 
screened and assigned a study ID number. This list should contain the subject identification 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
38 
 
number, full name and last known address in the even that study subjects need to be 
contacted beyond the time of study participation. 
 
CRF Completion 
The investigator will be responsible for the accuracy and timely completion of the 
information entered on the CRFs as well as the timely submission of CRFs to the sponsor. 
The CRF and source documents, including but not limited to subject’s history and physical 
exam (H & P), mammography, breast ultrasonography, additional breast imaging, breast 
MRI, cytology, histology, operative reports, progress reports, and discharge summaries must 
be available for review by the study monitor at each scheduled monitoring visit. The 
investigator will also allow clinical representatives of the sponsor, an independent auditor, 
the IRB, or regulatory bodies to review the information reported on the CRFs and to 
reconcile those data with source documents at the investigator’s location. 
 
Record Retention 
FDA regulations require that each investigator retain all records and documents for this study 
for a minimum of two years following the date on which study is completed, terminated, or 
discontinued. Should the investigator be unable to continue maintaining the records for this 
full time period, Atossa will provide assistance with document retention. No study related 
documentation, included but not limited to, the clinical trial protocol and amendments, 
IRB approval and correspondence, sponsor correspondence, SAEs, CRFs, monitoring 
reports, material accountability records, and the log of screened subjects may be destroyed 
without the written consent of Atossa.  However, Atossa requests that all records and 
documents for this study be maintained for at least 15 years following study completion. 
Should the investigator be unable to continue to maintain the records for this full time 
period, Atossa will provide assistance with document retention. No study related 
documentation, including but not limited to, the clinical trial protocol and amendments, IRB 
approval and correspondence, sponsor correspondence, AE, CRF, monitoring reports, 
material accountability records, and the log of screened subjects may be destroyed 
without the written consent of Atossa. 
 
Training 
All study personnel will be required to have the following training: 
• Intraductal administration procedural methods 
• Protocol review 
This training will be documented in the Clinical Trial Master File (CTMF). Study personnel 
that have undergone prior training in intraductal procedures will have this training 
documented in the CTMF. 
18.0 
PUBLICATION POLICY 
It is understood that there is an obligation to provide Atossa with complete data obtained 
during this study. The information obtained from this clinical trial will be used towards 
developing a body of knowledge related to intraductal therapy. All data derived from this 
clinical trial may be disclosed to the FDA and other regulatory agencies as required by 
applicable law. 
Sponsor encourages the publication of study data in reputable scientific journals and at 
seminars and conferences. Accordingly, the Institution and Principal Investigator agree not to 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
39 
 
publish the results of the Study without prior written review of Atossa. To that end the 
investigator and/or institution is required to furnish Atossa with a copy of any proposed 
publication, for review and comment, at least thirty (30) days prior to submission to a 
journal, scientific conference or disclosure to any third party. Any oral presentations or 
poster sessions must be submitted to Atossa fifteen (30) days prior to abstract submission for 
review. 
All rights, title and interest to the data and results arising from the study are the exclusive 
property of Atossa, subject to the provisions outlined and mutually agreed upon in the 
Clinical Trial Agreement. The Institution and/or Investigator shall have the right to retain 
copies of all their onsite data and results arising from its participation in the Study for its 
internal archival purposes.  
 
 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
40 
 
19.0 
REFERENCES 
 
1 Jamal A et al; Cancer statistics, 2006. CA Cancer J Clin 2006; 56(2): 106-30. 
2 Constatino JP, Gail M, Pee D, Anderson S, Redmon CK, Benichou J, Wieand HS. Validation 
studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer 
Inst. 1999; 91(18): 1541-48. 
3 Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. 
Implications for risk prediction. Cancer. 1994;73(3):643-51. 
4 Jones JL, Hughes KS, Kopans DB, Moore RH, Howard-McNatt M, Hughes SS, Lee NY, Roche 
CA, Siegel N, Gadd MA, Smith BL, Michaelson JS. Evaluation of hereditary risk in a 
mammography population. Clin Breast Cancer. 200; 6(1):38-44. 
5 Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, 
Eeles R, Matloff E, Tomlinson GE, Van't Veer L, Lynch HT, Olopade OI, Weber BL, Rebbeck 
TR. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a 
prospective cohort study. Lancet Oncol. 2006 Mar;7(3):223-9. 
6 Ease A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, 
Ghadirian P, Foulkes WD, Gorton-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing 
C, Ainsworth P, Sun P, Narod SA.Breast cancer risk following bilateral oophorectomy in BRCA1 and 
BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005; 23(30):7491-6. 
7 Fisher b, Costantino JP, Wicherham Dl, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah 
MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen 
for the prevention of breast cancer:current status of the National Adjuvant Breast and Bowel 
Project P-1 Study. J Natl Cancer Inst. 2005; 97 (22)  1652-62. 
8 Bao T, Prowell T, Stearns V. Chemoprevention of breast cancer: tamoxifen, raloxifene, 
and beyond. Am J Ther. 2006; 13(4):337-48. 
9 Wellings SR, Jenson HM, Marcum RG. An atlas of subgrowth pathology of the human 
breast with special reference to precancer lesions. JNCI 1975; 55: 231-73. 
10  Hartmann, NEJM 2015 
11 Cooper A. The Anatomy and Diseases of the Breast. Philadelphia: Lee and Blanchard, 1945. 
12 Sartorius OW, Morris PL, Benedict Dl, et al. Contrast ductography for recognition and 
localization of benign and malignant breast lesions: An improved technique. In Logan WW, Ed. 
Breast Carcinoma, New York: Wiley, 1977; 281-300. 
13 Dietz JR, Kim JA, Malycky JL, et al. Feasibility and technical considerations of mammary 
ductoscopy in human mastectomy specimens. Breast Journal 2000; 3:161-165. 
14 Love SM and Barsky SH. Anatomy of the nipple and breast ducts revisited. Cancer. 2004; 101(9): 
1947- 1957. 
15 LeBourgne R. Intraductal biopsy of certain pathologic processes of the breast. Surgery 1946; 1947-
54. 
16 Papanicolaou GN, Holmquist Dg, Bader Gm, Falk EA. Exfoliative cytology of the human 
mammary gland and its value in the diagnosis of cancer and other diseases of the breast. Cancer 
1958; 11:377-409. 
17 Buerhing GC. Screening for breast atypias using exfoliative cytology, Cancer 1979; 45(5): 1788-
99.  

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
41 
 
18 Wrensch MR, Petrakis NL, King EB, et al. Breast cancer incidence in women with abnormal 
cytology in nipples aspirates of breast fluid. Am J Epidem 1992; 135(2): 130-141. 
19 Wrensch MR, Petrakis NL, Miike R, King EB, Chew K, Neuhaus J, Lee MM, Rhys M. 
Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J Nat 
Cancer Inst 2001; 93(23): 1791-98. 
20 Sartorius OW, Smitth HA, Morris P, Benedict D, Friessen L. Cytologic evaluation of breast 
fluid in detection of breast disease. J Nat Cancer Inst 1977; 135:130-141. 
21 Goulet RJ, Badve S, Brannon-Peppas L, Rouch D, Huntley C, Storniolo AM. Pilot trial 
assessing the feasibility of intra-ductal delivery of epirubicin (epi)-containing nanoparticles 
(NP) via   InDuct® Microcatheter (IDBM). Proc Am Society Clin Oncol 2004; 22:828a. 
22 King B, Love SM, Rochman S, Kim J. The fourth international symposium on the intraductal 
approach to breast cancer, Santa Barbara,  California, 10-13  March 2005.  Breast Canc Res 2005; 
7: 198-204. 
23 Stearns V et al., Science Translational Medicine 2011; 3(106): 106-108 
24  Love SM et al, Cancer Prevention Research 2012;6:51-58 
25  Kuter I et al., Breast Cancer Research and Treatment 2012; 133:237-46 
26 Going JJ, Moffat DF. Escaping from Flatland: clinical and biological aspects of human 
mammary duct anatomy in three dimensions. J Pathol 2004;203(1):538-44. 
27 Mitoulas LR, Lai CT, Gurrin LC, Larsson M, Hartmann PE. Efficacy of breast milk expression using 
an electricbreast pump. J Hum Lact 2002 18(4):344-52. 
28 Mitoulas LR, Lai CT, Gurrin LC, Larsson M, Hartmann PE. Effect of vacuum profile on 
breast milk expression using an electric breast pump. J Hum Lact 2002 18(4):353-60. 
29 Dooley WC, Ljung B-M, Veronesi U, et al. Ductal lavage for detection of cellular atypia in 
women at high risk for breast cancer.  J. Nat Cancer Inst 2001: 93(21): 1624-63. 
30  Robertson JFR, Clinical Pharmacokinetics 2004; 43:529-538 
31 Faslodex® (fulvestrant) injection, full prescription information: http://www1.astrazeneca- 
us.com/pi/faslodex.pdf 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
  
42 
 
20.0 
APPENDICES 
 
 
 
Appendix A: ECOG Performance Scale 
 
 
Score 
Definition 
0 
Asymptomatic 
1 
Symptomatic but fully ambulatory 
2 
Symptomatic; in bed less than 50% of the day 
3 
Symptomatic; in bed more than 50 % of the day, but not bedridden 
4 
Bedridden 

 
 
43 
 
ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
 
 
 
Appendix B: Pain Analog Scale for Subject Assessment 
 
Indicate your level of comfort with a single mark on the line below or by telling your doctor 
or nurse, expressing your level of pain on a scale from 0 to 10. 0 Represents no pain and 10 
represent the worst possible pain. 
 
 
 
0 
10 
 
 
 
 
 
No Pain 
                                                                          Most Severe Pain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
 
44 
 
 
 
Faslodex® Full Prescribing Information  
 
 
 
 
 

ATOS-2015-007: An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal 
Fulvestrant in Women with Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy 
 
45 
 
 
Appendix C: New York Heart Association (NYHA) Classification 
 
Class Objective Assessment 
A 
No objective evidence of cardiovascular disease. No symptoms and no limitation in ordinary 
physical activity. 
B 
Objective evidence of minimal cardiovascular disease. Mild symptoms and slight limitation 
during ordinary activity. Comfortable at rest. 
C 
Objective evidence of moderately severe cardiovascular disease. Marked limitation in activity 
due to symptoms, even during less-than-ordinary activity. Comfortable only at rest. 
D 
Objective evidence of severe cardiovascular disease. Severe limitations. Experiences 
symptoms even while at rest. 

 
46